Why the study?
Cardiovascular events and arrhythmias are a major concern during pregnancy, where antiarrhythmic drugs require careful consideration due to potential adverse maternal and fetal effects.
What are the safety profiles and considerations for using antiarrhythmic drugs in pregnant women?
What are the safety profiles and considerations for using antiarrhythmic drugs in pregnant women?
This review highlights the need for individualized treatment and close monitoring when prescribing antiarrhythmic drugs during pregnancy due to potential fetal and maternal risks.
Answers are grounded in this paper and cite their sources.
Supports individualized antiarrhythmic selection in pregnancy; leaves open need for prospective safety trials.
Pregnancy entails notable physiological alterations and hormonal fluctuations that affect the well-being of both the fetus and the mother. Cardiovascular events and arrhythmias are a major concern during pregnancy, especially in women with comorbidities or a history of arrhythmias. This paper provides an overview of the prevalence, therapies, and prognoses of different types of arrhythmias during pregnancy. The administration of antiarrhythmic drugs (AADs) during pregnancy demands careful consideration because of their possible effect on the mother and fetus. AADs can cross the placenta or be present in breast milk, potentially leading to adverse effects such as teratogenicity, growth restriction, or premature birth. The safety profiles of different classes of AADs are discussed. Individualized treatment approaches and close monitoring of pregnant women prescribed AADs are essential to ensure optimal maternal and fetal outcomes.
No takes yet. Share an insight, caveat, or question.
Mariani et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: